AQEMIA

French company AQEMIA designs drug candidates for critical diseases leveraging its quantum and statistical mechanics algorithms. In contrast to AI platforms that rely on experimental data for training, AQEMIA takes a different approach to drug discovery by generating its own data using specialized quantum physics algorithms developed over 12 years of research at Oxford, Cambridge, and École Normale Supérieure (ENS). The company’s algorithms are reportedly 10,000x faster than existing ones.

Aqemia's drug discovery pipeline includes multiple projects, ranging from hit generation to vivo assays (therapeutic areas undisclosed), both in-house and collaborative programs.

Key customers and partnerships

The company secured partnerships with Big Pharma companies such as Sanofi (initiated in 2020 and extended in June 2022) to design and discover molecules in oncology. The duo also joined a USD 140 million multi-year collaboration in December 2023 to expand focus to various other therapeutic areas.

The company also partnered with Janssen in February 2022 to predict the potency of small molecules for specific targets in drug discovery projects.

AQEMIA entered into a partnership with pharmaceutical company Servier in December 2021 to accelerate drug discovery in immuno-oncology. The collaboration achieved a research milestone in June 2024, by identifying molecules effective toward an undruggable target.